TACE+分子靶向药物治疗肝细胞癌的效果分析

Effect Analysis of TACE and Molecular Targeted Drug in Hepatocellular Carcinoma

目的 评价肝细胞癌患者采用经皮肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)+分子靶向药物治疗的临床价值。方法 回顾性选择2016年2月—2021年2月期间于福建省立医院南院就诊的140例肝细胞癌患者,按照随机数表法分为观察组与对照组,各70例。对照组给予TACE治疗,观察组给予TACE+分子靶向药物治疗。比较两组患者的临床治疗效果。结果 观察组的客观缓解率(54.29%)与疾病控制率(84.29%)均高于对照组,差异有统计学意义(χ^(2)=6.537、16.042,P<0.05)。治疗后,观察组血管内皮生长因子低于对照组,差异有统计学意义(P<0.05)。两组患者腹泻、皮疹、乏力、消化道反应以及骨髓抑制情况对比,差异无统计学意义(P>0.05)。结论 肝细胞癌患者采用TACE+分子靶向药物治疗的效果突出,有利于提升疾病控制效果。

Objective To evaluate the clinical value of transcatheter arterial chemoembolization(TACE)plus molecular targeted drugs in hepatocellular carcinoma.Methods Retrospective selection total of 140 patients with hepatocellular carcinoma who were hospitalized in South Hospital of Fujian Provincial Hospital from February 2016 to February 2021 were divided into an observation group and a control group according to the random number table method,with 70 patients in each group.The control group was treated with TACE,while the observation group was treated with TACE+molecular targeted drugs.Compared the clinical treatment effects of the two groups of patients.Results The objective remission rate(54.29%)and disease control rate(84.29%)in the observation group were higher than those in the control group,and the difference was statistically significant(χ^(2)=6.537,16.042,P<0.05).After treatment,the vascular endothelial growth factor in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference between the two groups in terms of diarrhea,rash,fatigue,gastrointestinal reactions,and bone marrow suppression(P>0.05).Conclusion The effect of TACE+molecular targeted drug therapy on hepatocellular carcinoma patients is outstanding,which is conducive to improving the effect of disease control.